{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:24:17Z","timestamp":1776817457728,"version":"3.51.2"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00108-024-01725-z","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T20:13:36Z","timestamp":1717445616000},"page":"738-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chronisch-obstruktive Lungenerkrankung (COPD) \u2013 Eosinophilie und neue Arzneimitteltherapien","Chronic obstructive pulmonary disease (COPD): eosinophilia and novel drug therapies"],"prefix":"10.1007","volume":"65","author":[{"given":"L.","family":"Biener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pizarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Skowasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"1","key":"1725_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-2600(23)00461-7","volume":"12","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan\u00a0P (2024) GOLD COPD report: 2024 update. Lancet Respir Med 12(1):15\u201316","journal-title":"Lancet Respir Med"},{"issue":"7","key":"1725_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","volume":"207","author":"A Agust\u00ed","year":"2023","unstructured":"Agust\u00ed\u00a0A, Celli\u00a0BR, Criner\u00a0GJ, Halpin\u00a0D, Anzueto\u00a0A, Barnes\u00a0P et\u00a0al (2023) Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med 207(7):819\u2013837","journal-title":"Am J Respir Crit Care Med"},{"key":"1725_CR3","volume-title":"StatPearls","author":"A Widysanto","year":"2024","unstructured":"Widysanto\u00a0A, Mathew\u00a0G (2024) Chronic Bronchitis. In: StatPearls. StatPearls, Treasure Island (FL) ([cited 2024 Apr 23]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482437\/)"},{"issue":"1","key":"1725_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41533-021-00236-w","volume":"31","author":"S Kakavas","year":"2021","unstructured":"Kakavas\u00a0S, Kotsiou\u00a0OS, Perlikos\u00a0F, Mermiri\u00a0M, Mavrovounis\u00a0G, Gourgoulianis\u00a0K et\u00a0al (2021) Pulmonary function testing in COPD: looking beyond the curtain of FEV1. Npj Prim Care Respir Med 31(1):23\u201327","journal-title":"Npj Prim Care Respir Med"},{"key":"1725_CR5","doi-asserted-by":"publisher","first-page":"OA4936","DOI":"10.1183\/13993003.congress-2023.OA4936","volume-title":"Monitoring airway disease","author":"E Rapsomaniki","year":"2023","unstructured":"Rapsomaniki\u00a0E, Hughes\u00a0R, Make\u00a0B, Del Olmo\u00a0R, Papi\u00a0A, Price\u00a0D et\u00a0al (2023) Long-term outcomes in patients with Pre-COPD or PRISm in NOVELTY. In: Monitoring airway disease. European Respiratory Society, S OA4936 https:\/\/doi.org\/10.1183\/13993003.congress-2023.OA4936 (cited 2024 Apr 23)"},{"issue":"13","key":"1725_CR6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1056\/NEJMoa2204752","volume":"387","author":"MK Han","year":"2022","unstructured":"Han\u00a0MK, Ye\u00a0W, Wang\u00a0D, White\u00a0E, Arjomandi\u00a0M, Barjaktarevic\u00a0IZ et\u00a0al (2022) Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. N\u00a0Engl J Med 387(13):1173\u20131184","journal-title":"N Engl J Med"},{"issue":"3","key":"1725_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4046\/trd.2020.0026","volume":"83","author":"D Singh","year":"2020","unstructured":"Singh\u00a0D (2020) Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A\u00a0Biomarker of Inhaled Corticosteroid Effects. Tuberc Respir Dis 83(3):185\u2013194","journal-title":"Tuberc Respir Dis"},{"issue":"6","key":"1725_CR8","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/all.14661","volume":"76","author":"A Higham","year":"2021","unstructured":"Higham\u00a0A, Beech\u00a0A, Wolosianka\u00a0S, Jackson\u00a0N, Long\u00a0G, Kolsum\u00a0U et\u00a0al (2021) Type\u00a02 inflammation in eosinophilic chronic obstructive pulmonary disease. Allergy 76(6):1861\u20131864","journal-title":"Allergy"},{"issue":"1","key":"1725_CR9","first-page":"39","volume":"1","author":"S Saha","year":"2006","unstructured":"Saha\u00a0S, Brightling\u00a0CE (2006) Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 1(1):39\u201347","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"1725_CR10","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1183\/09031936.00162414","volume":"44","author":"D Singh","year":"2014","unstructured":"Singh\u00a0D, Kolsum\u00a0U, Brightling\u00a0CE, Locantore\u00a0N, Agusti\u00a0A, Tal-Singer\u00a0R (2014) Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir\u00a0J 44(6):1697\u20131700","journal-title":"Eur Respir J"},{"issue":"06","key":"1725_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1055\/a-1956-8800","volume":"77","author":"L Biener","year":"2023","unstructured":"Biener\u00a0L, Milger\u00a0K, Suhling\u00a0H, Korn\u00a0S, Pizarro\u00a0C, Skowasch\u00a0D (2023) Impact of short-term pausing of oral corticosteroids on blood eosinophil count in patients with severe asthma. Pneumologie 77(06):357\u2013362","journal-title":"Pneumologie"},{"issue":"10","key":"1725_CR12","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1164\/rccm.201701-0009LE","volume":"195","author":"OA Oshagbemi","year":"2017","unstructured":"Oshagbemi\u00a0OA, Burden\u00a0AM, Braeken\u00a0DCW, Henskens\u00a0Y, Wouters\u00a0EFM, Driessen\u00a0JHM et\u00a0al (2017) Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. Am J Respir Crit Care Med 195(10):1402\u20131404","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1725_CR13","doi-asserted-by":"publisher","first-page":"e000960","DOI":"10.1136\/bmjresp-2021-000960","volume":"8","author":"E Citgez","year":"2021","unstructured":"Citgez\u00a0E, Van Der Palen\u00a0J, Van Der Valk\u00a0P, Kerstjens\u00a0HAM, Brusse-Keizer\u00a0M (2021) Stability in eosinophil categorisation during subsequent severe exacerbations of COPD. BMJ Open Resp Res 8(1):e960","journal-title":"BMJ Open Resp Res"},{"issue":"9","key":"1725_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","volume":"193","author":"S Vedel-Krogh","year":"2016","unstructured":"Vedel-Krogh\u00a0S, Nielsen\u00a0SF, Lange\u00a0P, Vestbo\u00a0J, Nordestgaard\u00a0BG (2016) Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 193(9):965\u2013974","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1725_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1465-9921-11-122","volume":"11","author":"A Agusti","year":"2010","unstructured":"Agusti\u00a0A, Calverley\u00a0PMA, Celli\u00a0B, Coxson\u00a0HO, Edwards\u00a0LD, Lomas\u00a0DA et\u00a0al (2010) Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 11(1):122","journal-title":"Respir Res"},{"issue":"1","key":"1725_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","volume":"20","author":"F Maltais","year":"2019","unstructured":"Maltais\u00a0F, Bjermer\u00a0L, Kerwin\u00a0EM, Jones\u00a0PW, Watkins\u00a0ML, Tombs\u00a0L et\u00a0al (2019) Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res 20(1):238","journal-title":"Respir Res"},{"issue":"1","key":"1725_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41533-021-00218-y","volume":"31","author":"J Sulku","year":"2021","unstructured":"Sulku\u00a0J, Br\u00f6ms\u00a0K, H\u00f6gman\u00a0M, Janson\u00a0C, Lisspers\u00a0K, Malinovschi\u00a0A et\u00a0al (2021) Critical inhaler technique errors in Swedish patients with COPD: a\u00a0cross-sectional study analysing video-recorded demonstrations. npj Prim Care Respir Med 31(1):5","journal-title":"npj Prim Care Respir Med"},{"issue":"18","key":"1725_CR18","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson\u00a0DA, Barnhart\u00a0F, Brealey\u00a0N, Brooks\u00a0J, Criner\u00a0GJ, Day\u00a0NC et\u00a0al (2018) Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N\u00a0Engl J Med 378(18):1671\u20131680","journal-title":"N Engl J Med"},{"issue":"10","key":"1725_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson\u00a0GT, Rabe\u00a0KF, Martinez\u00a0FJ, Fabbri\u00a0LM, Wang\u00a0C, Ichinose\u00a0M et\u00a0al (2018) Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a\u00a0double-blind, parallel-group, multicentre, phase\u00a03 randomised controlled trial. Lancet Respir Med 6(10):747\u2013758","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1725_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe\u00a0KF, Martinez\u00a0FJ, Ferguson\u00a0GT, Wang\u00a0C, Singh\u00a0D, Wedzicha\u00a0JA et\u00a0al (2020) Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N\u00a0Engl J Med 383(1):35\u201348","journal-title":"N Engl J Med"},{"issue":"10125","key":"1725_CR21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi\u00a0A, Vestbo\u00a0J, Fabbri\u00a0L, Corradi\u00a0M, Prunier\u00a0H, Cohuet\u00a0G et\u00a0al (2018) Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a\u00a0double-blind, parallel group, randomised controlled trial. Lancet 391(10125):1076\u20131084","journal-title":"Lancet"},{"issue":"5","key":"1725_CR22","doi-asserted-by":"publisher","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","volume":"53","author":"D Singh","year":"2019","unstructured":"Singh\u00a0D, Agusti\u00a0A, Anzueto\u00a0A, Barnes\u00a0PJ, Bourbeau\u00a0J, Celli\u00a0BR et\u00a0al (2019) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir\u00a0J 53(5):1900164","journal-title":"Eur Respir J"},{"key":"1725_CR23","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2147\/COPD.S432963","volume":"18","author":"C Strange","year":"2023","unstructured":"Strange\u00a0C, Tkacz\u00a0J, Schinkel\u00a0J, Lewing\u00a0B, Agatep\u00a0B, Swisher\u00a0S et\u00a0al (2023) Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide\/Glycopyrrolate\/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study. Int J Chron Obstruct Pulmon Dis 18:2245\u20132256","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1725_CR24","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2018.0599","author":"J Graf","year":"2018","unstructured":"Graf\u00a0J, J\u00f6rres\u00a0RA, Lucke\u00a0T, Nowak\u00a0D, Vogelmeier\u00a0CF, Ficker\u00a0JH (2018) Medical Treatment of COPD. Dtsch \u00c4rztebl Int. https:\/\/doi.org\/10.3238\/arztebl.2018.0599 (Sep 14 [cited 2024 Apr 23])","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"3","key":"1725_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s11845-018-1738-9","volume":"187","author":"LF Shen","year":"2018","unstructured":"Shen\u00a0LF, Lv\u00a0XD, Chen\u00a0WY, Yang\u00a0Q, Fang\u00a0ZX, Lu\u00a0WF (2018) Effect of roflumilast on chronic obstructive pulmonary disease: a\u00a0systematic review and meta-analysis. Ir J Med Sci 187(3):731\u2013738","journal-title":"Ir J Med Sci"},{"issue":"2","key":"1725_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/lungindia.lungindia_498_19","volume":"38","author":"R Dhar","year":"2021","unstructured":"Dhar\u00a0R, Talwar\u00a0D, Singh\u00a0V, Dumra\u00a0H, Rajan\u00a0S, Jindal\u00a0SK (2021) Expert recommendations on the role of macrolides in chronic respiratory diseases. Lung India 38(2):174\u2013182","journal-title":"Lung India"},{"key":"1725_CR27","doi-asserted-by":"publisher","first-page":"585989","DOI":"10.1155\/2010\/585989","volume":"2010","author":"R Tkacova","year":"2010","unstructured":"Tkacova\u00a0R (2010) Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a\u00a0role? Review of the literature and future perspectives. Mediators Inflamm 2010:585989","journal-title":"Mediators Inflamm"},{"issue":"1","key":"1725_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12931-018-0944-3","volume":"19","author":"H Watz","year":"2018","unstructured":"Watz\u00a0H, Tetzlaff\u00a0K, Magnussen\u00a0H, Mueller\u00a0A, Rodriguez-Roisin\u00a0R, Wouters\u00a0EFM et\u00a0al (2018) Spirometric changes during exacerbations of COPD: a\u00a0post hoc analysis of the WISDOM trial. Respir Res 19(1):251","journal-title":"Respir Res"},{"issue":"11","key":"1725_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","volume":"67","author":"S Suissa","year":"2012","unstructured":"Suissa\u00a0S, Dell\u2019Aniello\u00a0S, Ernst\u00a0P (2012) Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 67(11):957\u2013963","journal-title":"Thorax"},{"issue":"1","key":"1725_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1183\/13993003.01391-2014","volume":"47","author":"S Hartl","year":"2016","unstructured":"Hartl\u00a0S, Lopez-Campos\u00a0JL, Pozo-Rodriguez\u00a0F, Castro-Acosta\u00a0A, Studnicka\u00a0M, Kaiser\u00a0B et\u00a0al (2016) Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir\u00a0J 47(1):113\u2013121","journal-title":"Eur Respir J"},{"issue":"21","key":"1725_CR31","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2013.5023","volume":"309","author":"JD Leuppi","year":"2013","unstructured":"Leuppi\u00a0JD, Schuetz\u00a0P, Bingisser\u00a0R, Bodmer\u00a0M, Briel\u00a0M, Drescher\u00a0T et\u00a0al (2013) Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 309(21):2223\u20132231","journal-title":"JAMA"},{"issue":"8","key":"1725_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(19)30176-6","volume":"7","author":"P Sivapalan","year":"2019","unstructured":"Sivapalan\u00a0P, Lapperre\u00a0TS, Janner\u00a0J, Laub\u00a0RR, Moberg\u00a0M, Bech\u00a0CS et\u00a0al (2019) Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a\u00a0multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med 7(8):699\u2013709","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1725_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","volume":"186","author":"M Bafadhel","year":"2012","unstructured":"Bafadhel\u00a0M, McKenna\u00a0S, Terry\u00a0S, Mistry\u00a0V, Pancholi\u00a0M, Venge\u00a0P et\u00a0al (2012) Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a\u00a0randomized placebo-controlled trial. Am J Respir Crit Care Med 186(1):48\u201355","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1725_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S2213-2600(23)00298-9","volume":"12","author":"S Ramakrishnan","year":"2024","unstructured":"Ramakrishnan\u00a0S, Jeffers\u00a0H, Langford-Wiley\u00a0B, Davies\u00a0J, Thulborn\u00a0SJ, Mahdi\u00a0M et\u00a0al (2024) Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a\u00a0non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial. Lancet Respir Med 12(1):67\u201377","journal-title":"Lancet Respir Med"},{"issue":"9","key":"1725_CR35","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.rmed.2013.05.001","volume":"107","author":"J Miller","year":"2013","unstructured":"Miller\u00a0J, Edwards\u00a0LD, Agust\u00ed\u00a0A, Bakke\u00a0P, Calverley\u00a0PMA, Celli\u00a0B et\u00a0al (2013) Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 107(9):1376\u20131384","journal-title":"Respir Med"},{"issue":"1","key":"1725_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/jcm8010069","volume":"8","author":"F Trinkmann","year":"2019","unstructured":"Trinkmann\u00a0F, Saur\u00a0J, Borggrefe\u00a0M, Akin\u00a0I (2019) Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)-Current Considerations for Clinical Practice. J\u00a0Clin Med 8(1):69","journal-title":"J Clin Med"},{"key":"1725_CR37","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.2147\/COPD.S110746","volume":"11","author":"C Pizarro","year":"2016","unstructured":"Pizarro\u00a0C, Herweg-Steffens\u00a0N, Buchenroth\u00a0M, Schulte\u00a0W, Schaefer\u00a0C, Hammerstingl\u00a0C et\u00a0al (2016) Invasive coronary angiography in patients with acute exacerbated COPD and elevated plasma troponin. Int J Chron Obstruct Pulmon Dis 11:2081\u20132089","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1725_CR38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.PA3013","author":"C Vogelmeier","year":"2023","unstructured":"Vogelmeier\u00a0C, Simons\u00a0S, Garbe\u00a0E, Sin\u00a0D, Hawkins\u00a0N, Manito\u00a0N et\u00a0al (2023) Increased risk of severe cardiovascular events following exacerbations of COPD: a\u00a0multi-database cohort study. In: Airway pharmacology and treatment [Internet. Eur Respir Soc. https:\/\/doi.org\/10.1183\/13993003.congress-2023.PA3013 ([cited 2024 Apr 23])","journal-title":"Eur Respir Soc"},{"key":"1725_CR39","doi-asserted-by":"publisher","first-page":"175346581775052","DOI":"10.1177\/1753465817750524","volume":"12","author":"AD Morgan","year":"2018","unstructured":"Morgan\u00a0AD, Zakeri\u00a0R, Quint\u00a0JK (2018) Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 12:1753465817750524","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"1725_CR40","doi-asserted-by":"publisher","first-page":"e0121377","DOI":"10.1371\/journal.pone.0121377","volume":"10","author":"C Pizarro","year":"2015","unstructured":"Pizarro\u00a0C, Schueler\u00a0R, Hammerstingl\u00a0C, Tuleta\u00a0I, Nickenig\u00a0G, Skowasch\u00a0D (2015) Impact of endoscopic lung volume reduction on right ventricular myocardial function. PLoS ONE 10(4):e121377","journal-title":"PLoS ONE"},{"key":"1725_CR41","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2021.RCT208","author":"M Bafadhel","year":"2021","unstructured":"Bafadhel\u00a0M, Rabe\u00a0KF, Singh\u00a0D, Jenkins\u00a0M, Dorinsky\u00a0P, Patel\u00a0M (2021) The relationship between eosinophils and reduction in major adverse cardiac events in ETHOS. In: Airway pharmacology and treatment [Internet. Eur Respir Soc. https:\/\/doi.org\/10.1183\/13993003.congress-2021.RCT208 ([cited 2024 Apr 23])","journal-title":"Eur Respir Soc"},{"issue":"1","key":"1725_CR42","first-page":"33","volume":"10","author":"JM Wells","year":"2023","unstructured":"Wells\u00a0JM, Criner\u00a0GJ, Halpin\u00a0DMG, Han\u00a0MK, Jain\u00a0R, Lange\u00a0P et\u00a0al (2023) Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial. Chronic Obstr Pulm Dis 10(1):33\u201345","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"2","key":"1725_CR43","doi-asserted-by":"publisher","first-page":"100306","DOI":"10.1016\/j.opresp.2024.100306","volume":"6","author":"AL Kersul","year":"2024","unstructured":"Kersul\u00a0AL, Cosio\u00a0BG (2024) Biologics in COPD. Open Respir Arch 6(2):100306","journal-title":"Open Respir Arch"},{"issue":"11","key":"1725_CR44","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","volume":"381","author":"GJ Criner","year":"2019","unstructured":"Criner\u00a0GJ, Celli\u00a0BR, Brightling\u00a0CE, Agusti\u00a0A, Papi\u00a0A, Singh\u00a0D et\u00a0al (2019) Benralizumab for the Prevention of COPD Exacerbations. N\u00a0Engl J Med 381(11):1023\u20131034","journal-title":"N Engl J Med"},{"key":"1725_CR45","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2147\/COPD.S294333","volume":"16","author":"ID Pavord","year":"2021","unstructured":"Pavord\u00a0ID, Chapman\u00a0KR, Bafadhel\u00a0M, Sciurba\u00a0FC, Bradford\u00a0ES, Schweiker Harris\u00a0S et\u00a0al (2021) Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis 16:1755\u20131770","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"1725_CR46","first-page":"290","volume":"65","author":"D Skowasch","year":"2024","unstructured":"Skowasch\u00a0D, Nitschmann\u00a0S (2024) Dupilumab bei chronisch-obstruktiver Lungenerkrankung. Inn Med 65(3):290\u2013291","journal-title":"Inn Med"},{"issue":"3","key":"1725_CR47","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt\u00a0SP, Rabe\u00a0KF, Hanania\u00a0NA, Vogelmeier\u00a0CF, Cole\u00a0J, Bafadhel\u00a0M et\u00a0al (2023) Dupilumab for COPD with Type\u00a02 Inflammation Indicated by Eosinophil Counts. N\u00a0Engl J Med 389(3):205\u2013214","journal-title":"N Engl J Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01725-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:03:11Z","timestamp":1719385391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01725-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1725"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01725-z","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"8 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Biener, C.\u00a0Pizarro und D.\u00a0Skowasch geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}